LATIGLUTENASE (ALV003) FOR USE IN THE TREATMENT OF SYMPTOMATIC CELIAC DISEASE, GLUTEN INTOLERANCE OR GLUTEN SENSITIVITY

摘要

A method is provided for reducing the severity and/or frequency of symptoms or clinical manifestations resulting from gluten ingestion by administering to a seropositive patient with symptomatic celiac disease, gluten intolerance, or gluten sensitivity latiglutenase (ALV003) in an amount from about 100 mg to about 1200 mg per day.